Uveal Neoplasm

Observed

← altered in cohorts of

SLC45A4

61 / 80 cases (76 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

AARD

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ADCY8

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

AGO2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ANXA13

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ASAP1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ATAD2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

C8orf76

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CCN3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CHRAC1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

COL14A1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

COL22A1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

COLEC10

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CYRIB

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DENND3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DEPTOR

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DERL1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DSCC1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EFR3A

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EIF3H

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ENPP2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EPPK1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EXT1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

FAM135B

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

FAM83A

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

FAM91A1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

FBXO32

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

FER1L6

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GPR20

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GRHL2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GSDMC

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

HAS2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

HHLA1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

KCNK9

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

KCNQ3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

KHDRBS3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

KLHL38

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

LRATD2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

LRRC6

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MAL2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MED30

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MRPL13

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MTBP

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MTSS1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MYC

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

NDRG1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

NDUFB9

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

NSMCE2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

NTAQ1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

OC90

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PHF20L1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PLEC

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

POU5F1B

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PTK2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PTP4A3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

RAD21

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

RNF139

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SAMD12

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SLA

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SLC30A8

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SNTB1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SQLE

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ST3GAL1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TAF2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TATDN1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TBC1D31

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TMEM65

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TMEM71

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TNFRSF11B

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TRAPPC9

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TRIB1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TRMT12

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TRPS1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

UTP23

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

WASHC5

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZFAT

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZHX1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZHX1-C8orf76

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZHX2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZNF572

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CPQ

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DCSTAMP

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EXOSC4

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GPAA1

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MFSD3

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

OSR2

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PPP1R16A

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PYCR3

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

RHPN1

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

RNF19A

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SLC25A32

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

VPS13B

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

VPS28

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZNF16

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZNF623

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GNAQ

40 / 80 cases (50 %) · ssm · uvm_tcga · largest of 3 cohorts

—

Observed

cbioportal

← altered in cohorts of

GNA11

36 / 80 cases (45 %) · ssm · uvm_tcga · largest of 3 cohorts

—

Observed

cbioportal

← altered in cohorts of

BAP1

26 / 80 cases (33 %) · ssm · uvm_tcga

—

Observed

cbioportal

Uveal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 60show all (up to 200)
→ investigated in trials for	Ipilimumabmonoclonal antibody 23 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 16 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Tebentafuspother 10 trials (7 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Aldesleukinother 9 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 9 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Dacarbazinesmall molecule 7 trials (1 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Crizotinibsmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Lifileucelcell therapy 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Afliberceptother 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Uveal Neoplasm	3	Observed	clinicaltrials	graph →

Uveal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 60show all (up to 200)

→ investigated in trials for

Ipilimumabmonoclonal antibody

23 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

16 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tebentafuspother

10 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aldesleukinother

9 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

9 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dacarbazinesmall molecule

7 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temozolomidesmall molecule

6 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Melphalansmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Crizotinibsmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lifileucelcell therapy

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Afliberceptother

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Uveal Neoplasm studied in …STUDIED_INderived10 of 237show all (up to 200)
→ studied in	NCT05524935Phase 2 · active not recruiting Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05607095Phase 1 · recruiting A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07804186Phase 3 · recruiting Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02678572Phase 3 · completed Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05903937Phase 1 · not yet recruiting Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06070012Phase 2 · recruiting Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07183852Phase 1 · not yet recruiting Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma · condition mapped CURATED_BROADER · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07803562Phase 2 · not yet recruiting Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp · condition mapped CURATED_BROADER · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07076550Phase 1 · terminated A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma · condition mapped CURATED_BROADER · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03025256Phase 1 · active not recruiting Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease · condition mapped CURATED_BROADER · 237 trials mapped (71 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →

Uveal Neoplasm studied in …STUDIED_INderived10 of 237show all (up to 200)

→ studied in

NCT05524935Phase 2 · active not recruiting

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT05607095Phase 1 · recruiting

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT07804186Phase 3 · recruiting

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT02678572Phase 3 · completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT05903937Phase 1 · not yet recruiting

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT06070012Phase 2 · recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT07183852Phase 1 · not yet recruiting

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma · condition mapped CURATED_BROADER · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT07803562Phase 2 · not yet recruiting

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp · condition mapped CURATED_BROADER · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT07076550Phase 1 · terminated

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma · condition mapped CURATED_BROADER · 237 trials mapped (71 active)

—

Observed

→ studied in

NCT03025256Phase 1 · active not recruiting

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease · condition mapped CURATED_BROADER · 237 trials mapped (71 active)

—

Observed